Victory Capital Management
RXRX icon

Victory Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Victory Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$164K Buy
53,269
+3,611
+7% +$14K ﹤0.01% 2217
2025
Q4 		$203K Buy
49,658
+11,313
+30% +$56K ﹤0.01% 2204
2025
Q3 		$187K Buy
38,345
+1,287
+3% +$6.76K ﹤0.01% 2232
2025
Q2 		$188K Buy
37,058
+695
+2% +$3.41K ﹤0.01% 2260
2025
Q1 		$192K Sell
36,363
-3,550
-9% -$25.9K ﹤0.01% 2232
2024
Q4 		$270K Buy
39,913
+12,519
+46% +$84.2K ﹤0.01% 2164
2024
Q3 		$181K Buy
27,394
+5,503
+25% +$39.4K ﹤0.01% 2242
2024
Q2 		$164K Buy
21,891
+2,598
+13% +$22.7K ﹤0.01% 2235
2024
Q1 		$192K Sell
19,293
-1,148
-6% -$12.8K ﹤0.01% 2230
2023
Q4 		$202K Buy
20,441
+5,195
+34% +$37K ﹤0.01% 2235
2023
Q3 		$117K Buy
15,246
+2,912
+24% +$29.1K ﹤0.01% 2284
2023
Q2 		$92.1K Sell
12,334
-288
-2% -$2.02K ﹤0.01% 2323
2023
Q1 		$84.2K Sell
12,622
-575
-4% -$4.56K ﹤0.01% 2382
2022
Q4 		$102K Buy
13,197
+1,135
+9% +$11.1K ﹤0.01% 2358
2022
Q3 		$128K Buy
+12,062
New +$122K ﹤0.01% 2438
2021
Q3 		– Sell
-6,620
Closed -$242K – 2837
2021
Q2 		$242K Buy
+6,620
New +$196K ﹤0.01% 2486

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Victory Capital Management's RXRX Position: Q1 2026 in Review

Victory Capital Management increased its Recursion Pharmaceuticals (RXRX) stake by 7.3% in Q1 2026, buying an estimated $14K and bringing the position to 53,269 shares worth $164K. The position accounts for ﹤0.01% of the portfolio, ranked #2217.

Victory Capital Management first reported a position in RXRX in Q2 2021 and has held it in 16 quarters since. The position peaked at $270K in Q4 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Victory Capital Management held 53,269 shares of Recursion Pharmaceuticals worth $164K as of Q1 2026.
  • Victory Capital Management bought 3,611 Recursion Pharmaceuticals shares in Q1 2026, an estimated $14K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #2217 holding.
  • Victory Capital Management first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 16 quarters since.
  • Victory Capital Management's Recursion Pharmaceuticals position peaked at $270K in Q4 2024.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.